Advisor Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Advisor Group’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,262	Closed	-$76K	–	5382
2018 Q3	$76K	Buy	+4,262	New	+$73.2K	﹤0.01%	2965
2018 Q1	–	Sell	-100	Closed	–	–	5172
2017 Q4	$0	Sell	100 -700	-88%	-$3.33K	﹤0.01%	5167
2017 Q3	$1K	Hold	800	–	–	﹤0.01%	4783
2017 Q2	$1K	Sell	800 -1,085	-58%	-$2.33K	﹤0.01%	4739
2017 Q1	$5K	Buy	1,885 +1,085	+136%	+$2.51K	﹤0.01%	4154
2016 Q4	$2K	Hold	800	–	–	﹤0.01%	4291
2016 Q3	$2K	Buy	+800	New	+$2.49K	﹤0.01%	4239

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Advisor Group's ECYT Position: Q4 2018 in Review

Advisor Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 4,262 shares — an estimated $76K sold.

Advisor Group first reported a position in ECYT in Q3 2016 and held it in 7 quarters. The position peaked at $76K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Advisor Group reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Advisor Group sold 4,262 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $76K.
Advisor Group first reported a position in Endocyte, Inc. Common Stock in Q3 2016 and held it in 7 quarters.
Advisor Group's Endocyte, Inc. Common Stock position peaked at $76K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Advisor Group's 13F filing for Q4 2018, filed 11 Feb 2019.